A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood

NCT07081932 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-14

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.

Conditions

  • Healthy

Interventions

DRUG

Nerandomilast

Nerandomilast

DRUG

Bosentan

Bosentan

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2025-09-27
Completion
2025-10-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07081932 on ClinicalTrials.gov